Terumo Corporation · TSE:4543
Terumo — Investor Presentation (November 2014)
10 slides from Terumo's investor presentation, Nov 5, 2014
Slide 1: General Hospital Company, Toward Sustainable Growth
General Hospital Company, Toward Sustainable Growth Terumo Corporation Director and Executive Vice President, President of General Hospital Company Hiroshi Matsumura November 5, 2014
Slide 2: 1H Domestic Sales in Negative Growth
1H Domestic Sales in Negative Growth General Hospital Company: monthly performance in year-on-year comparison 110% Recoil reduction in demand Temporary decline in hospital following tax hike beds utilization rate Restrained patients consultation 105% 103% 101% 100% 98% 95% 95% 95% 94% 90% Apr May
Slide 3: Declined Beds Utilization Due to "Revision of Bed Classification"
Declined Beds Utilization Due to “Revision of Bed Classification” Present Year 2015 Oct, 2014, all hospitals are 7:1 required to report their nursing care system nursing needs to MHLW. Short-term acute care (360K hospital beds) •Review of intensity criterion for nursing care needs •Tighten assessmen
Slide 4: Business Profit on the Road to Improvement
Business Profit on the Road to Improvement Business Profit Margin of General Hospital Company 16% 14% 12% 10% FY13_2Q FY13_3Q FY13_4Q FY14_1Q FY14_2Q © Terumo Corporation 2014/11/5 4/10
Slide 5: For Profitable and Sustainable Growth
For Profitable and Sustainable Growth Boost sales growth for “Drug & Device”, and “DM and Consumer Healthcare” Accelerate profitability improvement in “General Hospital Products” and “Pharmaceutical and Nutrition” % Profitability Improvement Sales Profitability DM Expansion and Consumer Drug Hea
Slide 6: Create High-Value Added Business for Hospital Market
Growth Strategy: #1 Create High-Value Added Business for Hospital Market Become a solution provider for Medical Professionals and Patients Prevent accidental needle-stick and malpractice, Promote safe practice Closed anticancer IV catheter, Safety syringe drug infusion system SURFLO V3 Safe Infusion
Slide 7: Expand B2B Business for Pharmaceutical Companies
Growth Strategy: #2 Expand B2B Business for Pharmaceutical Companies Benefit from high-growth pharmaceutical market Vaccine, biotechnology-based medicine (antibody, protein) Provide pharmaceutical companies with high-value added functions High quality, easy-to-use, and drug Safety Tailor dev
Slide 8: Global Strategy
Growth Strategy: #3 Global Strategy Expand Sales by direct marketing in JP and Asia Expand high-value added products through B2B business in EU and U.S. Sales Improve Profitability for Business Profit Margin (BPM) M$ U.S. General Hospital Products business 110 10% 100 Sales 50 0% BPM -10 FY12 FY13
Slide 9: Transform Product Portfolio of Overseas Business: Europe
Transform Product Portfolio of Overseas Business 【Europe】 Low profitability business for hospitals: transition its activities of production and sales Expand high-value added, high-growth B2B business for pharmaceutical companies Sales Business Profit EUR M Margin 100 50% 80 40% 60 病院 Hospitals 3
Slide 10: IR Contact
IR Contact Terumo Corporation Corporate Communication (IR) Dept. E-mail: [email protected] Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not i